{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:27Z","timestamp":1791924207229,"version":"4.3.4"},"reference-count":39,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR21\/00059"],"award-info":[{"award-number":["JR21\/00059"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00812"],"award-info":[{"award-number":["PI20\/00812"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01357"],"award-info":[{"award-number":["PI24\/01357"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Immune checkpoint inhibitors are essential treatments for many oncologic diseases, but with well-known immune-related adverse events, such as acute interstitial nephritis (ICI-AIN). We investigated novel potential biomarkers that could assist in the diagnosis and follow-up of this condition and that are related to the active pathogenic pathways involved. We measured urinary soluble PD-1, PD-L1 and PD-L2, as well as chemokines CXCL5, CXCL9, CXCL10, CXCL11, CCL2, CCL3, CCL5 and cytokines IL-6 and IL-12p70 performing a Luminex assay in urine from patients with ICI-AIN (n = 35) and compared them with patients with AIN from other causes (non-ICI AIN) (n = 29) and ATN (n = 26). We found that CXCL5, CXCL9, CXCL10, CXCL11, CCL5 and IL-6 were higher in patients with ICI-AIN than in those with ATN, and all of them but CXCL9 and IL-6 were also higher in patients with ICI-AIN compared with non-ICI AIN. We also determined these molecules at follow-up for ICI-AIN patients (40 samples from 22 patients) and found that concentrations of CXCL9, CXCL10, CXCL11 and CCL2 decreased after treatment. The decrease of CXCL9 and CXCL10 correlated with greater kidney function recovery at one-year follow-up. These molecules could serve as noninvasive biomarkers and may aid fine patient monitoring.<\/jats:p>","DOI":"10.3390\/ijms27031240","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T16:13:48Z","timestamp":1769444028000},"page":"1240","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Urinary Chemokines in the Diagnosis and Monitoring of Immune Checkpoint Inhibitor-Associated Nephritis"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0890-0666","authenticated-orcid":false,"given":"Francisco","family":"Gomez-Preciado","sequence":"first","affiliation":[{"name":"Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), 08907 Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Facultat de Medicina i Ci\u00e8ncies de la Salut, Universitat de Barcelona (UB), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Martinez-Valenzuela","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), 08907 Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3521-6066","authenticated-orcid":false,"given":"Paula","family":"Anton-Pampols","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Can Ruti Hospital, 08916 Badalona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1974-9874","authenticated-orcid":false,"given":"Xavier","family":"Fulladosa","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), 08907 Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Jove","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Catalan Institute of Oncology, Bellvitge Healthcare Campus Comprehensive Cancer Center, 08908 Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Preclinical and Experimental Research in Thoracic Tumors (PRETT), Bellvitge Biomedical Research Institute (IDIBELL), 08908 Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9674-5554","authenticated-orcid":false,"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Catalan Institute of Oncology, Bellvitge Healthcare Campus Comprehensive Cancer Center, 08908 Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Preclinical and Experimental Research in Thoracic Tumors (PRETT), Bellvitge Biomedical Research Institute (IDIBELL), 08908 Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-8558","authenticated-orcid":false,"given":"Josep Mar\u00eda","family":"Cruzado","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), 08907 Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1135-7588","authenticated-orcid":false,"given":"Joan","family":"Torras","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), 08907 Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Draibe","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), 08907 Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A Comprehensive Review of Immune Checkpoint Inhibitors for Cancer Treatment","volume":"143","author":"Hossain","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s12276-020-0435-8","article-title":"Recent Insights of T Cell Receptor-Mediated Signaling Pathways for T Cell Activation and Development","volume":"52","author":"Hwang","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","article-title":"T Cell Receptor (TCR) Signaling in Health and Disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41581-022-00630-8","article-title":"Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury","volume":"18","author":"Sprangers","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological Features of Acute Kidney Injury Associated with Immune Checkpoint Inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1523-1755.1998.00001.x","article-title":"The Clinical Spectrum of Tubulointerstitial Nephritis","volume":"54","author":"Rastegar","year":"1998","journal-title":"Kidney Int."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Hakroush, S., Kopp, S.B., Tampe, D., Gersmann, A.-K., Korsten, P., Zeisberg, M., and Tampe, B. (2021). Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.624547"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e010680","DOI":"10.1136\/jitc-2024-010680","article-title":"Urine Proteomics Defines an Immune Checkpoint-Associated Nephritis Signature","volume":"13","author":"Long","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Singh, S., Long, J.P., Tchakarov, A., Dong, Y., Yee, C., and Lin, J.S. (2022). Tertiary Lymphoid Structure Signatures Are Associated with Immune Checkpoint Inhibitor Related Acute Interstitial Nephritis. JCI Insight, in press.","DOI":"10.1172\/jci.insight.165108"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","article-title":"Tertiary Lymphoid Structures in Anticancer Immunity","volume":"24","author":"Teillaud","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tortonese, S., Isnard, P., Anglicheau, D., Lebraud, E., and Rabant, M. (2025). Phenotypic and Molecular Signatures in Acute Interstitial Nephritis: FR-OR057. J. Am. Soc. Nephrol., 36.","DOI":"10.1681\/ASN.202538vyftc3"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0140-6736(20)30540-7","article-title":"The Link between Kidney Disease and Cancer: Complications and Treatment","volume":"396","author":"Malyszko","year":"2020","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Xu, L.-Y., Zhao, H.-Y., Yu, X.-J., Wang, J.-W., Zheng, X.-Z., Jiang, L., Wang, S.-X., Liu, G., and Yang, L. (2023). Clinicopathological Features of Kidney Injury Related to Immune Checkpoint Inhibitors: A Systematic Review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041349"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/ndt\/gfaa049","article-title":"Impact of Acute Kidney Injury on Anticancer Treatment Dosage and Long-Term Outcomes: A Pooled Analysis of European Organisation for Research and Treatment of Cancer Trials","volume":"36","author":"Neven","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s00330-022-09158-8","article-title":"Imaging Features of Immune Checkpoint Inhibitor-Related Nephritis with Clinical Correlation: A Retrospective Series of Biopsy-Proven Cases","volume":"33","author":"Awiwi","year":"2022","journal-title":"Eur. Radiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ekir.2022.11.020","article-title":"Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors","volume":"8","author":"Farooqui","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e006222","DOI":"10.1136\/jitc-2022-006222","article-title":"Soluble and Cell-Based Markers of Immune Checkpoint Inhibitor-Associated Nephritis","volume":"11","author":"Sise","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Martinez Valenzuela, L., Draibe, J., Bestard, O., Fulladosa, X., G\u00f3mez-Preciado, F., Ant\u00f3n, P., Nadal, E., Jov\u00e9, M., Cruzado, J.M., and Torras, J. (2021). Urinary Cytokines Reflect Renal Inflammation in Acute Tubulointerstitial Nephritis: A Multiplex Bead-Based Assay Assessment. J. Clin. Med., 10.","DOI":"10.3390\/jcm10132986"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e168950","DOI":"10.1172\/JCI168950","article-title":"Identification and Validation of Urinary CXCL9 as a Biomarker for Diagnosis of Acute Interstitial Nephritis","volume":"133","author":"Moledina","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.medj.2022.12.007","article-title":"Immune Signatures Predict Development of Autoimmune Toxicity in Patients with Cancer Treated with Immune Checkpoint Inhibitors","volume":"4","author":"Berner","year":"2023","journal-title":"Med"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"sfae200","DOI":"10.1093\/ckj\/sfae200","article-title":"Urinary Soluble PD-1 as a Biomarker of Checkpoint Inhibitor-Induced Acute Tubulointerstitial Nephritis","volume":"17","author":"Fulladosa","year":"2024","journal-title":"Clin. Kidney J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/ckj\/sfac194","article-title":"The Association between Acute Kidney Injury and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis","volume":"16","author":"Kanbay","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/ckj\/sfaa027","article-title":"Acute Tubulointerstitial Nephritis Induced by Checkpoint Inhibitors versus Classical Acute Tubulointerstitial Nephritis: Are They the Same Disease?","volume":"14","author":"Draibe","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.kint.2024.09.017","article-title":"Diagnosis and Management of Immune Checkpoint Inhibitor\u2013Associated Nephrotoxicity: A Position Statement from the American Society of Onco-Nephrology","volume":"107","author":"Herrmann","year":"2025","journal-title":"Kidney Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical Features and Outcomes of Immune Checkpoint Inhibitor\u2013Associated AKI: A Multicenter Study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e005646","DOI":"10.1136\/jitc-2022-005646","article-title":"Shorter versus Longer Corticosteroid Duration and Recurrent Immune Checkpoint Inhibitor-Associated AKI","volume":"10","author":"Gupta","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000531297","article-title":"Immune Checkpoint Inhibitor-Associated Nephrotoxicity","volume":"148","author":"Mamlouk","year":"2024","journal-title":"Nephron"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e004660","DOI":"10.1136\/rmdopen-2024-004660","article-title":"Immune Checkpoint Molecules Performance in ANCA Vasculitis","volume":"10","author":"Manrique","year":"2024","journal-title":"RMD Open"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/art.40164","article-title":"Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis","volume":"69","author":"Fukasawa","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.imlet.2020.09.001","article-title":"Abnormal Membrane-Bound and Soluble Programmed Death Ligand 2 (PD-L2) Expression in Systemic Lupus Erythematosus Is Associated with Disease Activity","volume":"227","author":"Tong","year":"2020","journal-title":"Immunol. Lett."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kushlinskii, N.E., Kovaleva, O.V., Gratchev, A.N., Alferov, A.A., Kuzmin, Y.B., Sokolov, N.Y., Tsekatunov, D.A., Ryzhavskaya, I.B., Kuznetsov, I.N., and Kushlinskii, D.N. (2025). Assessing the Clinical Relevance of Soluble PD-1 and PD-L1: A Multi-Cohort Study Across Diverse Tumor Types and Prognostic Implications. Biomedicines, 13.","DOI":"10.3390\/biomedicines13020500"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Khan, M., Zhao, Z., Arooj, S., Fu, Y., and Liao, G. (2020). Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.587460"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/JLB.3MR0218-062R","article-title":"Role of Chemokines in Ectopic Lymphoid Structures Formation in Autoimmunity and Cancer","volume":"104","author":"Nerviani","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Tampe, D., Kopp, S.B., Baier, E., Hakroush, S., and Tampe, B. (2022). Compartmentalization of Intrarenal Programmed Cell Death Protein 1-Ligand 1 and Its Receptor in Kidney Injury Related to Immune Checkpoint Inhibitor Nephrotoxicity. Front. Med., 9.","DOI":"10.3389\/fmed.2022.902256"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1074\/jbc.M207006200","article-title":"Chemokine-Cytokine Cross-talk","volume":"278","author":"Chandrasekar","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"29406","DOI":"10.1074\/jbc.M112.348946","article-title":"The chemokine CCL5 regulates glucose uptake and AMP kinase signaling in activated T cells to facilitate chemotaxis","volume":"287","author":"Chan","year":"2012","journal-title":"J. Biol. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/3\/1240\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:15:15Z","timestamp":1769750115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/3\/1240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27031240"],"URL":"https:\/\/doi.org\/10.3390\/ijms27031240","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]}}}